RxSight (RXST) vs Warby Parker (WRBY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Warby Parker (WRBY) has outperformed RxSight (RXST) over the past year, gaining 1.4% versus a loss of 40.9%. Over five years, WRBY leads with a -54.4% price change compared with -64.2% for RXST. Warby Parker is the larger company by market cap ($3.08 billion vs $201.7 million), about 15.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RXST | WRBY |
|---|---|---|
| Share price | $4.85 | $24.95 |
| Market cap | $201.73M | $3.08B |
| 1-day change | +1.04% | -1.42% |
| YTD return | -53.45% | +14.50% |
| 1-year return | -40.93% | +1.42% |
| 5-year return | -64.23% | -54.43% |
| P/E ratio (TTM) | — | 415.83 |
| Forward P/E | — | 40.58 |
| EPS (TTM) | $-1.14 | $0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $871.90M |
| Revenue growth (YoY) | — | +13.04% |
| Net income (latest FY) | — | $1.64M |
| Gross margin | — | 53.97% |
| Operating margin | — | -0.61% |
| Net margin | — | 0.19% |
| 52-week high | $13.22 | $31.00 |
| 52-week low | $4.48 | $14.96 |
| Distance from 52-week high | -63.31% | -19.52% |
| Analyst consensus | none | buy |
| Avg. price target upside | +56.08% | +22.08% |
| Average volume | 862.64K | 2.85M |
| Shares outstanding | 41.59M | 108.24M |
| Employees | 461 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Ophthalmic Goods | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Warby Parker is about 15.3 times larger than RxSight by market value ($3.08B vs $201.73M).
- WRBY has outperformed RXST by 42.3 percentage points over the past year.
About RxSight
RXST stock →RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Health Care · Ophthalmic Goods · 461 employees
About Warby Parker
WRBY stock →Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada.
Health Care · Ophthalmic Goods · 2,275 employees
RXST vs WRBY FAQ
Which is bigger, RxSight or Warby Parker?
Warby Parker (WRBY) is larger, with a market capitalization of $3.08B compared with $201.73M for RxSight (RXST).
Which stock has performed better over the past year, RXST or WRBY?
WRBY returned +1.42% over the past 12 months, compared with -40.93% for RXST (price return, excluding dividends). Past performance does not predict future results.
Are RxSight and Warby Parker in the same industry?
Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.